The Conversation (0)
Mallinckrodt (NYSE:MNK) announced today that it has entered into a multiyear agreement with Medtronic (NYSE:MDT) to advance availability in the U.S. of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.
Mallinckrodt (NYSE:MNK) announced today that it has entered into a multiyear agreement with Medtronic (NYSE:MDT) to advance availability in the U.S. of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.
As quoted in the press release:
Under the agreement, the two companies will collaborate on the development and testing of Mallinckrodt’s future intrathecal products for use in Medtronic’s SynchroMed(R) Programmable Infusion System. The companies will also develop joint marketing and sales programs to increase awareness and adoption of these drug delivery therapies. Specific terms of the agreement are not being disclosed.